Author

Elie Marcheteau

ORCID 0000-0001-6630-9682Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

Franck GallardoiD· 3 shared Charlotte Quentin-FroignantiD· 2 shared Luigi André AgrofoglioiD· 2 shared Sandrine Kappler‐Gratias· 2 shared Vincent RoyiD· 2 shared A. Proust· 1 shared Alicia MasiD· 1 shared Alı́ AlejoiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Franck GallardoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Use of ANCHOR viruses to validate radiative, physical and chemical decontamination systems in operational conditions.

Franck Gallardo, V. Poirier, Charlotte Quentin-Froignant, Thomas Figueroa, Romain Volmer, A. Proust, C. Menard, M. Rosa-Calatrava, Morgane Mousnier, O. Authier, Dani Lainisalo, Pertti Lainisalo, Tero Ingelius, M. Grandadam, Elie Marcheteau

This paper validates ANCHOR viruses as a platform for evaluating disinfection methods across chemical, physical, and radiative modalities in operational conditions.

Journal of Hospital Infection · May 4, 2026Peer-reviewedMicrobiology

LAVR-289, a new acyclo-nucleoside phosphonate having broad-spectrum activity against herpesviruses.

Sandrine Kappler‐Gratias, Charlotte Quentin-Froignant, Elie Marcheteau, José Fernandez, David Boutolleau, Virginie Garcia, Vincent Roy, Luigi André Agrofoglio, Franck Gallardo

This study evaluates LAVR-289, a new antiviral compound, showing broad-spectrum activity against herpesviruses and resistance to existing treatments.

bioRxiv · Feb 20, 2025 · PreprintMicrobiology

In vitro and in vivo Antiviral Activity of the Acyclic Nucleoside Phosphonate Prodrug LAVR-289 against Poxvirus and African Swine Fever Virus Replication

Elie Marcheteau, Estelle Mosca, Gaelle Frénois-Veyrat, Sandrine Kappler‐Gratias, Laetitia Boutin, Sokunthea Top, Thomas Mathieu, Cyril Colas, Patrick Favetta, Tony Garnier, Peggy Barbe, Mathilde Keck, Daniel Gillet, Alicia Mas, Alı́ Alejo, , Franck Gallardo

This study evaluates LAVR-289, a nucleoside analogue, showing antiviral activity against poxviruses and ASFV in vitro and in vivo with no toxicity.

bioRxiv · Feb 20, 2025 · PreprintMicrobiology